An Epstein-Barr virus positive natural killer lymphoma xenograft derived for drug testing.
Identifieur interne : 001653 ( Main/Exploration ); précédent : 001652; suivant : 001654An Epstein-Barr virus positive natural killer lymphoma xenograft derived for drug testing.
Auteurs : Susan Li Er Loong [Singapour] ; Jacqueline Siok Gek Hwang ; Soon-Thye Lim ; Swee Peng Yap ; Miriam Tao ; Tsung-Wen Chong ; Leonard Hwan Cheong Tan ; Hung HuynhSource :
- Leukemia & lymphoma [ 1029-2403 ] ; 2008.
Descripteurs français
- KwdFr :
- Activation enzymatique (effets des médicaments et des substances chimiques), Adulte d'âge moyen (MeSH), Animaux (MeSH), Anticorps monoclonaux (administration et posologie), Anticorps monoclonaux humanisés (MeSH), Apoptose (effets des médicaments et des substances chimiques), Bévacizumab (MeSH), Caspase-3 (métabolisme), Cellules cancéreuses en culture (MeSH), Cellules tueuses naturelles (effets des médicaments et des substances chimiques), Cellules tueuses naturelles (virologie), Cyclophosphamide (administration et posologie), Doxorubicine (administration et posologie), Herpèsvirus humain de type 4 (isolement et purification), Humains (MeSH), Infections à virus Epstein-Barr (traitement médicamenteux), Infections à virus Epstein-Barr (virologie), Injections péritoneales (MeSH), Lymphome T périphérique (traitement médicamenteux), Lymphome T périphérique (virologie), Mâle (MeSH), Poly(ADP-ribose) polymerases (métabolisme), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Sirolimus (administration et posologie), Souris (MeSH), Souris SCID (MeSH), Technique de Western (MeSH), Transplantation hétérologue (MeSH), Transplantation tumorale (MeSH).
- MESH :
- administration et posologie : Anticorps monoclonaux, Cyclophosphamide, Doxorubicine, Sirolimus.
- effets des médicaments et des substances chimiques : Activation enzymatique, Apoptose, Cellules tueuses naturelles.
- isolement et purification : Herpèsvirus humain de type 4.
- métabolisme : Caspase-3, Poly(ADP-ribose) polymerases.
- traitement médicamenteux : Infections à virus Epstein-Barr, Lymphome T périphérique.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- virologie : Cellules tueuses naturelles, Infections à virus Epstein-Barr, Lymphome T périphérique.
- Adulte d'âge moyen, Animaux, Anticorps monoclonaux humanisés, Bévacizumab, Cellules cancéreuses en culture, Humains, Injections péritoneales, Mâle, Souris, Souris SCID, Technique de Western, Transplantation hétérologue, Transplantation tumorale.
English descriptors
- KwdEn :
- Animals (MeSH), Antibodies, Monoclonal (administration & dosage), Antibodies, Monoclonal, Humanized (MeSH), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Apoptosis (drug effects), Bevacizumab (MeSH), Blotting, Western (MeSH), Caspase 3 (metabolism), Cyclophosphamide (administration & dosage), Doxorubicin (administration & dosage), Enzyme Activation (drug effects), Epstein-Barr Virus Infections (drug therapy), Epstein-Barr Virus Infections (virology), Herpesvirus 4, Human (isolation & purification), Humans (MeSH), Injections, Intraperitoneal (MeSH), Killer Cells, Natural (drug effects), Killer Cells, Natural (virology), Lymphoma, T-Cell, Peripheral (drug therapy), Lymphoma, T-Cell, Peripheral (virology), Male (MeSH), Mice (MeSH), Mice, SCID (MeSH), Middle Aged (MeSH), Neoplasm Transplantation (MeSH), Poly(ADP-ribose) Polymerases (metabolism), Sirolimus (administration & dosage), Transplantation, Heterologous (MeSH), Tumor Cells, Cultured (MeSH).
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Cyclophosphamide, Doxorubicin, Sirolimus.
- drug effects : Apoptosis, Enzyme Activation, Killer Cells, Natural.
- drug therapy : Epstein-Barr Virus Infections, Lymphoma, T-Cell, Peripheral.
- isolation & purification : Herpesvirus 4, Human.
- chemical , metabolism : Caspase 3, Poly(ADP-ribose) Polymerases.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- virology : Epstein-Barr Virus Infections, Killer Cells, Natural, Lymphoma, T-Cell, Peripheral.
- Animals, Antibodies, Monoclonal, Humanized, Bevacizumab, Blotting, Western, Humans, Injections, Intraperitoneal, Male, Mice, Mice, SCID, Middle Aged, Neoplasm Transplantation, Transplantation, Heterologous, Tumor Cells, Cultured.
Abstract
Natural killer (NK) lymphomas occurring more frequently in the Far East and South America respond poorly to anthracycline-based regimens. Here we report an in vivo NK lymphoma xenograft (NK-S1) derived from the testicular metastasis of a patient with an extranodal NK lymphoma (nasal type). The NK-S1 xenograft, established in severe combined immune deficient (SCID) mice retained the same imunophenotypic features as the original tumor. NK-S1 disseminated intra-abdominally to the testis, intestine and liver. Although doxorubicin, rapamycin, bevacizumab, rapamycin-doxorubicin, and bevacizumab-doxorubicin had no effects on the growth of subcutaneous NK-S1 xenografts, intraperitoneal (IP) delivery of cyclophosphamide caused complete tumor regression; this tumor regression was associated with apoptosis, upregulation of activated caspase-3, and cleaved Poly(ADP-ribose) polymerase (PARP). In an IP model of NK lymphoma, cyclophosphamide also prolonged the survival of mice and potently inhibited tumor dissemination and ascites formation. Our data suggest that the NK-S1 xenograft is a useful tool for screening preclinical drugs, and cyclophosphamide may be a useful drug for the treatment of this disease.
DOI: 10.1080/10428190802043879
PubMed: 18452087
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">An Epstein-Barr virus positive natural killer lymphoma xenograft derived for drug testing.</title>
<author><name sortKey="Loong, Susan Li Er" sort="Loong, Susan Li Er" uniqKey="Loong S" first="Susan Li Er" last="Loong">Susan Li Er Loong</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Cellular and Molecular Research, Department of Radiation Oncology, National Cancer Centre, Singapore.</nlm:affiliation>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>Division of Cellular and Molecular Research, Department of Radiation Oncology, National Cancer Centre</wicri:regionArea>
<wicri:noRegion>National Cancer Centre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hwang, Jacqueline Siok Gek" sort="Hwang, Jacqueline Siok Gek" uniqKey="Hwang J" first="Jacqueline Siok Gek" last="Hwang">Jacqueline Siok Gek Hwang</name>
</author>
<author><name sortKey="Lim, Soon Thye" sort="Lim, Soon Thye" uniqKey="Lim S" first="Soon-Thye" last="Lim">Soon-Thye Lim</name>
</author>
<author><name sortKey="Yap, Swee Peng" sort="Yap, Swee Peng" uniqKey="Yap S" first="Swee Peng" last="Yap">Swee Peng Yap</name>
</author>
<author><name sortKey="Tao, Miriam" sort="Tao, Miriam" uniqKey="Tao M" first="Miriam" last="Tao">Miriam Tao</name>
</author>
<author><name sortKey="Chong, Tsung Wen" sort="Chong, Tsung Wen" uniqKey="Chong T" first="Tsung-Wen" last="Chong">Tsung-Wen Chong</name>
</author>
<author><name sortKey="Tan, Leonard Hwan Cheong" sort="Tan, Leonard Hwan Cheong" uniqKey="Tan L" first="Leonard Hwan Cheong" last="Tan">Leonard Hwan Cheong Tan</name>
</author>
<author><name sortKey="Huynh, Hung" sort="Huynh, Hung" uniqKey="Huynh H" first="Hung" last="Huynh">Hung Huynh</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18452087</idno>
<idno type="pmid">18452087</idno>
<idno type="doi">10.1080/10428190802043879</idno>
<idno type="wicri:Area/Main/Corpus">001615</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001615</idno>
<idno type="wicri:Area/Main/Curation">001615</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001615</idno>
<idno type="wicri:Area/Main/Exploration">001615</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">An Epstein-Barr virus positive natural killer lymphoma xenograft derived for drug testing.</title>
<author><name sortKey="Loong, Susan Li Er" sort="Loong, Susan Li Er" uniqKey="Loong S" first="Susan Li Er" last="Loong">Susan Li Er Loong</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Cellular and Molecular Research, Department of Radiation Oncology, National Cancer Centre, Singapore.</nlm:affiliation>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>Division of Cellular and Molecular Research, Department of Radiation Oncology, National Cancer Centre</wicri:regionArea>
<wicri:noRegion>National Cancer Centre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hwang, Jacqueline Siok Gek" sort="Hwang, Jacqueline Siok Gek" uniqKey="Hwang J" first="Jacqueline Siok Gek" last="Hwang">Jacqueline Siok Gek Hwang</name>
</author>
<author><name sortKey="Lim, Soon Thye" sort="Lim, Soon Thye" uniqKey="Lim S" first="Soon-Thye" last="Lim">Soon-Thye Lim</name>
</author>
<author><name sortKey="Yap, Swee Peng" sort="Yap, Swee Peng" uniqKey="Yap S" first="Swee Peng" last="Yap">Swee Peng Yap</name>
</author>
<author><name sortKey="Tao, Miriam" sort="Tao, Miriam" uniqKey="Tao M" first="Miriam" last="Tao">Miriam Tao</name>
</author>
<author><name sortKey="Chong, Tsung Wen" sort="Chong, Tsung Wen" uniqKey="Chong T" first="Tsung-Wen" last="Chong">Tsung-Wen Chong</name>
</author>
<author><name sortKey="Tan, Leonard Hwan Cheong" sort="Tan, Leonard Hwan Cheong" uniqKey="Tan L" first="Leonard Hwan Cheong" last="Tan">Leonard Hwan Cheong Tan</name>
</author>
<author><name sortKey="Huynh, Hung" sort="Huynh, Hung" uniqKey="Huynh H" first="Hung" last="Huynh">Hung Huynh</name>
</author>
</analytic>
<series><title level="j">Leukemia & lymphoma</title>
<idno type="eISSN">1029-2403</idno>
<imprint><date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term>
<term>Antibodies, Monoclonal (administration & dosage)</term>
<term>Antibodies, Monoclonal, Humanized (MeSH)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Apoptosis (drug effects)</term>
<term>Bevacizumab (MeSH)</term>
<term>Blotting, Western (MeSH)</term>
<term>Caspase 3 (metabolism)</term>
<term>Cyclophosphamide (administration & dosage)</term>
<term>Doxorubicin (administration & dosage)</term>
<term>Enzyme Activation (drug effects)</term>
<term>Epstein-Barr Virus Infections (drug therapy)</term>
<term>Epstein-Barr Virus Infections (virology)</term>
<term>Herpesvirus 4, Human (isolation & purification)</term>
<term>Humans (MeSH)</term>
<term>Injections, Intraperitoneal (MeSH)</term>
<term>Killer Cells, Natural (drug effects)</term>
<term>Killer Cells, Natural (virology)</term>
<term>Lymphoma, T-Cell, Peripheral (drug therapy)</term>
<term>Lymphoma, T-Cell, Peripheral (virology)</term>
<term>Male (MeSH)</term>
<term>Mice (MeSH)</term>
<term>Mice, SCID (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Neoplasm Transplantation (MeSH)</term>
<term>Poly(ADP-ribose) Polymerases (metabolism)</term>
<term>Sirolimus (administration & dosage)</term>
<term>Transplantation, Heterologous (MeSH)</term>
<term>Tumor Cells, Cultured (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Activation enzymatique (effets des médicaments et des substances chimiques)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Animaux (MeSH)</term>
<term>Anticorps monoclonaux (administration et posologie)</term>
<term>Anticorps monoclonaux humanisés (MeSH)</term>
<term>Apoptose (effets des médicaments et des substances chimiques)</term>
<term>Bévacizumab (MeSH)</term>
<term>Caspase-3 (métabolisme)</term>
<term>Cellules cancéreuses en culture (MeSH)</term>
<term>Cellules tueuses naturelles (effets des médicaments et des substances chimiques)</term>
<term>Cellules tueuses naturelles (virologie)</term>
<term>Cyclophosphamide (administration et posologie)</term>
<term>Doxorubicine (administration et posologie)</term>
<term>Herpèsvirus humain de type 4 (isolement et purification)</term>
<term>Humains (MeSH)</term>
<term>Infections à virus Epstein-Barr (traitement médicamenteux)</term>
<term>Infections à virus Epstein-Barr (virologie)</term>
<term>Injections péritoneales (MeSH)</term>
<term>Lymphome T périphérique (traitement médicamenteux)</term>
<term>Lymphome T périphérique (virologie)</term>
<term>Mâle (MeSH)</term>
<term>Poly(ADP-ribose) polymerases (métabolisme)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Sirolimus (administration et posologie)</term>
<term>Souris (MeSH)</term>
<term>Souris SCID (MeSH)</term>
<term>Technique de Western (MeSH)</term>
<term>Transplantation hétérologue (MeSH)</term>
<term>Transplantation tumorale (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Cyclophosphamide</term>
<term>Doxorubicin</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux</term>
<term>Cyclophosphamide</term>
<term>Doxorubicine</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Apoptosis</term>
<term>Enzyme Activation</term>
<term>Killer Cells, Natural</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Epstein-Barr Virus Infections</term>
<term>Lymphoma, T-Cell, Peripheral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Activation enzymatique</term>
<term>Apoptose</term>
<term>Cellules tueuses naturelles</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Herpesvirus 4, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Herpèsvirus humain de type 4</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Caspase 3</term>
<term>Poly(ADP-ribose) Polymerases</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Caspase-3</term>
<term>Poly(ADP-ribose) polymerases</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à virus Epstein-Barr</term>
<term>Lymphome T périphérique</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Cellules tueuses naturelles</term>
<term>Infections à virus Epstein-Barr</term>
<term>Lymphome T périphérique</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Epstein-Barr Virus Infections</term>
<term>Killer Cells, Natural</term>
<term>Lymphoma, T-Cell, Peripheral</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Antibodies, Monoclonal, Humanized</term>
<term>Bevacizumab</term>
<term>Blotting, Western</term>
<term>Humans</term>
<term>Injections, Intraperitoneal</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, SCID</term>
<term>Middle Aged</term>
<term>Neoplasm Transplantation</term>
<term>Transplantation, Heterologous</term>
<term>Tumor Cells, Cultured</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Animaux</term>
<term>Anticorps monoclonaux humanisés</term>
<term>Bévacizumab</term>
<term>Cellules cancéreuses en culture</term>
<term>Humains</term>
<term>Injections péritoneales</term>
<term>Mâle</term>
<term>Souris</term>
<term>Souris SCID</term>
<term>Technique de Western</term>
<term>Transplantation hétérologue</term>
<term>Transplantation tumorale</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Natural killer (NK) lymphomas occurring more frequently in the Far East and South America respond poorly to anthracycline-based regimens. Here we report an in vivo NK lymphoma xenograft (NK-S1) derived from the testicular metastasis of a patient with an extranodal NK lymphoma (nasal type). The NK-S1 xenograft, established in severe combined immune deficient (SCID) mice retained the same imunophenotypic features as the original tumor. NK-S1 disseminated intra-abdominally to the testis, intestine and liver. Although doxorubicin, rapamycin, bevacizumab, rapamycin-doxorubicin, and bevacizumab-doxorubicin had no effects on the growth of subcutaneous NK-S1 xenografts, intraperitoneal (IP) delivery of cyclophosphamide caused complete tumor regression; this tumor regression was associated with apoptosis, upregulation of activated caspase-3, and cleaved Poly(ADP-ribose) polymerase (PARP). In an IP model of NK lymphoma, cyclophosphamide also prolonged the survival of mice and potently inhibited tumor dissemination and ascites formation. Our data suggest that the NK-S1 xenograft is a useful tool for screening preclinical drugs, and cyclophosphamide may be a useful drug for the treatment of this disease.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18452087</PMID>
<DateCompleted><Year>2008</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>01</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1029-2403</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>49</Volume>
<Issue>6</Issue>
<PubDate><Year>2008</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Leukemia & lymphoma</Title>
<ISOAbbreviation>Leuk Lymphoma</ISOAbbreviation>
</Journal>
<ArticleTitle>An Epstein-Barr virus positive natural killer lymphoma xenograft derived for drug testing.</ArticleTitle>
<Pagination><MedlinePgn>1161-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/10428190802043879</ELocationID>
<Abstract><AbstractText>Natural killer (NK) lymphomas occurring more frequently in the Far East and South America respond poorly to anthracycline-based regimens. Here we report an in vivo NK lymphoma xenograft (NK-S1) derived from the testicular metastasis of a patient with an extranodal NK lymphoma (nasal type). The NK-S1 xenograft, established in severe combined immune deficient (SCID) mice retained the same imunophenotypic features as the original tumor. NK-S1 disseminated intra-abdominally to the testis, intestine and liver. Although doxorubicin, rapamycin, bevacizumab, rapamycin-doxorubicin, and bevacizumab-doxorubicin had no effects on the growth of subcutaneous NK-S1 xenografts, intraperitoneal (IP) delivery of cyclophosphamide caused complete tumor regression; this tumor regression was associated with apoptosis, upregulation of activated caspase-3, and cleaved Poly(ADP-ribose) polymerase (PARP). In an IP model of NK lymphoma, cyclophosphamide also prolonged the survival of mice and potently inhibited tumor dissemination and ascites formation. Our data suggest that the NK-S1 xenograft is a useful tool for screening preclinical drugs, and cyclophosphamide may be a useful drug for the treatment of this disease.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Loong</LastName>
<ForeName>Susan Li Er</ForeName>
<Initials>SL</Initials>
<AffiliationInfo><Affiliation>Division of Cellular and Molecular Research, Department of Radiation Oncology, National Cancer Centre, Singapore.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hwang</LastName>
<ForeName>Jacqueline Siok Gek</ForeName>
<Initials>JS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lim</LastName>
<ForeName>Soon-Thye</ForeName>
<Initials>ST</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yap</LastName>
<ForeName>Swee Peng</ForeName>
<Initials>SP</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tao</LastName>
<ForeName>Miriam</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chong</LastName>
<ForeName>Tsung-Wen</ForeName>
<Initials>TW</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tan</LastName>
<ForeName>Leonard Hwan Cheong</ForeName>
<Initials>LH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Huynh</LastName>
<ForeName>Hung</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Leuk Lymphoma</MedlineTA>
<NlmUniqueID>9007422</NlmUniqueID>
<ISSNLinking>1026-8022</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2S9ZZM9Q9V</RegistryNumber>
<NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>80168379AG</RegistryNumber>
<NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>8N3DW7272P</RegistryNumber>
<NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.4.2.30</RegistryNumber>
<NameOfSubstance UI="D011065">Poly(ADP-ribose) Polymerases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="C505409">Casp3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000068258" MajorTopicYN="N">Bevacizumab</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020031" MajorTopicYN="N">Epstein-Barr Virus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007274" MajorTopicYN="N">Injections, Intraperitoneal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016411" MajorTopicYN="N">Lymphoma, T-Cell, Peripheral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009368" MajorTopicYN="N">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011065" MajorTopicYN="N">Poly(ADP-ribose) Polymerases</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014183" MajorTopicYN="N">Transplantation, Heterologous</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year>
<Month>5</Month>
<Day>3</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2008</Year>
<Month>11</Month>
<Day>5</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2008</Year>
<Month>5</Month>
<Day>3</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">18452087</ArticleId>
<ArticleId IdType="pii">792728827</ArticleId>
<ArticleId IdType="doi">10.1080/10428190802043879</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Singapour</li>
</country>
</list>
<tree><noCountry><name sortKey="Chong, Tsung Wen" sort="Chong, Tsung Wen" uniqKey="Chong T" first="Tsung-Wen" last="Chong">Tsung-Wen Chong</name>
<name sortKey="Huynh, Hung" sort="Huynh, Hung" uniqKey="Huynh H" first="Hung" last="Huynh">Hung Huynh</name>
<name sortKey="Hwang, Jacqueline Siok Gek" sort="Hwang, Jacqueline Siok Gek" uniqKey="Hwang J" first="Jacqueline Siok Gek" last="Hwang">Jacqueline Siok Gek Hwang</name>
<name sortKey="Lim, Soon Thye" sort="Lim, Soon Thye" uniqKey="Lim S" first="Soon-Thye" last="Lim">Soon-Thye Lim</name>
<name sortKey="Tan, Leonard Hwan Cheong" sort="Tan, Leonard Hwan Cheong" uniqKey="Tan L" first="Leonard Hwan Cheong" last="Tan">Leonard Hwan Cheong Tan</name>
<name sortKey="Tao, Miriam" sort="Tao, Miriam" uniqKey="Tao M" first="Miriam" last="Tao">Miriam Tao</name>
<name sortKey="Yap, Swee Peng" sort="Yap, Swee Peng" uniqKey="Yap S" first="Swee Peng" last="Yap">Swee Peng Yap</name>
</noCountry>
<country name="Singapour"><noRegion><name sortKey="Loong, Susan Li Er" sort="Loong, Susan Li Er" uniqKey="Loong S" first="Susan Li Er" last="Loong">Susan Li Er Loong</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001653 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001653 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Bois |area= RapamycinFungusV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:18452087 |texte= An Epstein-Barr virus positive natural killer lymphoma xenograft derived for drug testing. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:18452087" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a RapamycinFungusV1
This area was generated with Dilib version V0.6.38. |